Explore Eli Lilly and Company stock: obesity drug tirzepatide sales +115%, new retatrutide diabetes data, and Kisunla ...
The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results